louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05986942: Evaluation of the Postoperative Agitation Prevention and Analgesic Efficacy of Perioperative Dexmedetomidine Infusion in a Pediatric Patient Group to Undergo Tonsillectomy and Adenoidectomy
Official title: Evaluation of the Postoperative Agitation Prevention and Analgesic Efficacy of Perioperative Dexmedetomidine Infusion in a Pediatric Patient Group to Undergo Tonsillectomy and Adenoidectomy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anxiety
Postoperative Pain
Bleeding
Keywords: Dexmedetomidine
tonsillectomy
adenoidectomy
postoperative anxiety
Lead sponsor: Medipol University
Sponsor class: OTHER
First posted: 2023-08-14
Enrollment: 80
Sex: ALL
Minimum age (years): 2
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with ASA 1-2, aged 2-10 years, scheduled for elective tonsillectomy and/or adenoidectomy operation will be included

Brief summary: Dexmedetomidine is a drug known for its pain-relieving and restlessness-reducing effects. The purpose of this run is to use the association between this use during surgery and the attrition of post-operative pain and discomfort. In the research, laboratory and monitoring results will be obtained before, during and after the operation. Postoperative patient complaints will be evaluated at the postoperative service visit. This study is decided on a completely voluntary basis.


Eligibility criteria: Inclusion Criteria:

Patients with ASA 1-2, aged 2-10 years, scheduled for elective tonsillectomy and/or adenoidectomy operation will be included.

Exclusion Criteria:

developmental delay anxiety disorder Known history of allergy to alpha-2 agonistic agents use of antipsychotic medication beta blocker use of anticonvulsant drugs chronic pain syndrome with cardiac and craniofacial anomalies

Primary outcomes:
measure: postoperative pain
timeFrame: Pain was evaluated at 0, 2, 4, 6 and 8 hours postoperatively.
measure: postoperative anxiety
timeFrame: anxiety was evaluated at 0, 2, 4, 6 and 8 hours postoperatively.
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Medipol University
Study officials:
affiliation: Medipol University
name: Yaşar G Gül
role: STUDY_DIRECTOR
References:
citation: Patel A, Davidson M, Tran MC, Quraishi H, Schoenberg C, Sant M, Lin A, Sun X. Dexmedetomidine infusion for analgesia and prevention of emergence agitation in children with obstructive sleep apnea syndrome undergoing tonsillectomy and adenoidectomy. Anesth Analg. 2010 Oct;111(4):1004-10. doi: 10.1213/ANE.0b013e3181ee82fa. Epub 2010 Aug 12.
citation: Lin R, Ansermino JM. Dexmedetomidine in paediatric anaesthesia. BJA Educ. 2020 Oct;20(10):348-353. doi: 10.1016/j.bjae.2020.05.004. Epub 2020 Jul 22. No abstract available.
Clinical trial NCT00304642: A Study to Assess the Pharmacokinetics of Dapivirine (TMC120) Vaginal Microbicide Gel
Official title: A Study to Assess the Pharmacokinetics of Dapivirine (TMC120) Vaginal Microbicide Gel in Healthy HIV-Negative Women.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: HIV Infections
Keywords: HIV-1
HIV Seronegativity
Lead sponsor: International Partnership for Microbicides, Inc.
Sponsor class: INDUSTRY
First posted: 2006-03-20
Enrollment: 18
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Approximately 18 women will be enrolled in this single-center, double-blind, randomized Phase I study to assess vaginal tissue and fluid levels, plasma levels and pharmacokinetics of dapivirine (TMC120) gel, which will be applied for 10 consecutive days in 18 healthy HIV-negative women ages 18 to 50. Volunteers will be randomized in a 1:1:1 ratio to receive 2.5mL dapivirine vaginal microbicide gel at one of three concentrations.


Eligibility criteria: Inclusion Criteria:

* HIV-negative
* Willing to participate and sign and informed consent form.
* Willing to be tested for HIV and to use an experimental vaginal gel.
* Willing to use a reliable form of contraception during the study.
* Willing to undergo pelvic examinations with colposcopy according to the protocol throughout the study.
* Normal cervical assessment.
* Willing to abstain from using any vaginal product (other than the study product).
* Willing to be sexually abstinent from Day 1 until completion of study product use on Day 10.

Exclusion Criteria:

* Currently pregnant or breast-feeding.
* Currently has any clinically detectable abnormality on the vulva, vaginal walls or cervix.
* Currently has laboratory confirmed gonorrhea, chlamydia, trichomonas or syphilis, has Genital Ulcer Disease (GUD) or vaginal candidiasis symptoms; or has an HSV-2 lesion as indicated by clinical diagnosis or laboratory test.
* Symptomatic bacterial vaginosis (BV) and unwilling to undergo treatment.
* Current use of injection drugs.

Primary outcomes:
measure: To assess plasma levels and pharmacokinetics of dapivirine applied vaginally. To measure vaginal fluid and vaginal tissue levels of dapivirine at various time after application of the gel.
Secondary outcomes:
Other outcomes:
Locations:
city: Bloemfontein
country: South Africa
facility: Farmovs-Parexel
Study officials:
affiliation: IPM
name: Zeda Rosenberg, ScD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01173770: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ADC3680B in Healthy Volunteers
Official title: A Double-Blind Randomized, Placebo-Controlled, Dose Escalating Study to Assess The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ADC3680B Administered Orally to Healthy Volunteers and to Investigate Food Effects on Pharmacokinetics After Single Oral Doses of ADC3680B
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: Pulmagen Therapeutics
Sponsor class: INDUSTRY
First posted: 2010-08-02
Enrollment: 52
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is a First-In-Man study designed to examine the safety, tolerability, pharmacokinetics and functional activity of ADC3680B after single and multiple doses in healthy male volunteers.


Eligibility criteria: Inclusion Criteria:

* Healthy male subjects between the ages of 18 and 55 years
* Body Mass Index (BMI) of 18 to 30 kg/m2
* Signed and dated written informed consent prior to admission into the study
* Willing and able to comply with the requirements of the protocol and available to complete the study

Exclusion Criteria:

* Evidence of history of any clinically significant medical disorder
* History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity

Primary outcomes:
measure: Safety and tolerability of single doses of ADC3680B determined by adverse event reporting, clinical laboratory tests, vital signs and ECGs
timeFrame: 2 days
measure: Safety and tolerability of multiple doses of ADC3680B determined by adverse event reporting, clinical laboratory tests, vital signs and ECGs
timeFrame: 8 days
Secondary outcomes:
measure: Single dose pharmacokinetics of ADC3680B
timeFrame: 2 days
measure: Multiple dose pharmacokinetic of ADC3680B
timeFrame: 8 days
measure: Pharmacokinetics of ADC3680B under fasted and fed conditions
timeFrame: 2 days
measure: Eosinophil shape change in response to stimulation with PGD2 in whole blood ex vivo
timeFrame: Pre-dose and up to 48 hours post-dose
Other outcomes:
Locations:
city: Merthyr Tydfil
country: United Kingdom
facility: Simbec
Study officials:
affiliation: Simbec Research
name: Febbraro
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02208570: Predictability of the Pulse Pressure Variation (PPV) During Spontaneous Ventilation on the Incidence of Hypotension During Induction of Anesthesia
Official title: Predictability of the Pulse Pressure Variation During Spontaneous Ventilation on the Incidence of Hypotension During Induction of Anesthesia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hypotension
Keywords: Hypotension during anesthesia induction
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2014-08-05
Enrollment: 172
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to find out the predictability of the pulse pressure variation during spontaneous ventilation on the incidence of hypotension during induction of anesthesia.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing general anesthesia induction with intravenous anesthesia using propofol and remifentanil
* Patients requiring invasive arterial blood pressure monitoring for the surgery

Exclusion Criteria:

* Refusal of consent
* Patients with heart disease (symptomatic valvular heart disease, intracardiac shunt, pulmonary hypertension with pulmonary systolic arterial pressure exceeding 40mmHg)
* FEV1 ≤ 50% predicted FEV1
* Patients with chronic renal failure
* ASA class IV, V, VI
* Systolic arterial blood pressure below 90mmHg before induction of anesthesia

Primary outcomes:
measure: Changes of heart rate and systolic arterial blood pressure from baseline values immediately before tracheal intubation
timeFrame: Three minutes after anesthesia agent injection
Secondary outcomes:
measure: Changes of heart rate and systolic arterial blood pressure from baseline values, three minutes before intubation
timeFrame: Three minutes before endotracheal intubation
measure: Changes of heart rate and systolic arterial blood pressure from baseline values, three minutes after intubation
timeFrame: Three minutes after endotracheal intubation
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT00626470: Prospective Trial on Trochanteric Femur Fractures Treated With or Without a Trochanter Support Plate
Official title: A Prospective Randomised Study of Unstable Trochanteric Femur Fractures Treated With Dynamic Hip Screw With and Without a Trochanter Support Plate
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Femoral Fractures
Keywords: Trochanter
Femur
Fracture
Lead sponsor: St. Olavs Hospital
Sponsor class: OTHER
First posted: 2008-02-29
Enrollment: 100
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Fractures just below the hip often are treated with a so called Gliding Screw and Plate (DHS). Recently a new additional plate called a Trochanter Support Plate (TSP) which attaches to the DHS has become available which is claimed to give extra support to the fracture. In a prospective randomised study we wish to test the hypothesis that the TSP does not give any additional stability to the fracture treated with the DHS.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of unstable trochanteric femur fracture.(Evans-Jensen class.3-5)
* (can include; Patients with cognitive problems (ie. dementia etc)

Exclusion Criteria:

* Patients with pathological fractures
* Multitrauma patients
* Patients not able to walk before the fracture
* Under 19 years old.
* Patients with fractures needing other treatments than gliding hip screws
* Reverse oblique fractures.

Primary outcomes:
measure: Fracture movement postoperatively
timeFrame: One year
Secondary outcomes:
measure: Reoperation
timeFrame: One year
measure: Pain postoperatively
timeFrame: one year
measure: Hip function postoperatively
timeFrame: one year
measure: Fracture healing
timeFrame: one year
measure: complications postoperatively
timeFrame: one year
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: Ortopaedic Department, St.Olavs Hospital
Study officials:
affiliation: St. Olavs Hospital
name: James Haddon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00350870: CBT With Disulfiram and Contingency Management
Official title: Maximizing the Efficacy of Cognitive Behavioral Therapy With Medication and Contingency Management
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cocaine Abuse
Keywords: disulfiram
cognitive behavioral therapy
contingency management
drug abuse therapy
educational/resource design/development
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2006-07-11
Enrollment: 181
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: This is a study of four treatments for chronic cocaine use and may help study participants to control their drug use. All participants will receive weekly individual cognitive behavioral therapy (CBT).

Detailed description: This study will compare four types of treatment involving skills training and incentives for attending sessions or taking study medication. Disulfiram is a widely prescribed deterrent to alcohol use. In addition to weekly cognitive behavioral therapy (CBT), participants will be assigned to one of the following treatments:

1. placebo
2. disulfiram
3. placebo plus incentives for cocaine abstinence and medication compliance (prize CM)
4. disulfiram plus incentives for cocaine abstinence and medication compliance

Eligibility criteria: Inclusion Criteria:

* 18-50 year old
* cocaine dependent
* willing to sign consent
* willing to accept randomization to intervention

Exclusion Criteria:

* significant medical conditions
* psychiatric disorder with current use of prescribed psychotropic medication
* lifetime schizophrenia or bipolar disorder
* suicidality or homicidality
* unlikely to be able to complete 1 year follow up
* unable to speak or read English at a third grade level

Primary outcomes:
measure: Change in Cocaine Use by Self Report
timeFrame: 12 weeks
measure: Change in Cocaine Use by Urine Toxicology Results
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: New Haven
country: United States
facility: APT Foundation
state: Connecticut
Study officials:
affiliation: Yale University
name: Kathleen M. Carroll, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Worhunsky PD, Stevens MC, Carroll KM, Rounsaville BJ, Calhoun VD, Pearlson GD, Potenza MN. Functional brain networks associated with cognitive control, cocaine dependence, and treatment outcome. Psychol Addict Behav. 2013 Jun;27(2):477-88. doi: 10.1037/a0029092. Epub 2012 Jul 9.
citation: Carroll KM, Nich C, Shi JM, Eagan D, Ball SA. Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug Alcohol Depend. 2012 Nov 1;126(1-2):224-31. doi: 10.1016/j.drugalcdep.2012.05.019. Epub 2012 Jun 12.
Clinical trial NCT01567670: Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray
Official title: Clinical Controlled Trial on Extinction of Opioidergic Binge Eating Disorder (BED) With Intranasal Naloxone Administration
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Binge Eating Disorder
Lead sponsor: Lightlake Sinclair Ltd.
Sponsor class: OTHER
First posted: 2012-03-30
Enrollment: 138
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The investigators are studying a new treatment for one subtype of obesity. Obesity is not a disease. It is a symptom of several different diseases. These diseases have distinct etiologies, being caused by aberrations in different mechanisms. Forms of obesity caused by such non-critical mechanisms might be corrected fairly easily and safely. The investigators are interested in overeating and obesity that is caused by the opioidergic system. The opioidergic system appears to be responsible for a subtype of obesity associated with binge eating disorder (BED). People, especially with the right genetic predisposition, can become addicted to foods that release endorphins, in the way that people become addicted to exogenous opiates and other drugs that release endorphins. The particular application in our proposed clinical trial is for intranasal (IN) naloxone. The peak levels of naloxone were similar and the bioavailability of naloxone intranasally was 100% (the same) of that available IV." IN administration of naloxone has since been broadly tested in humans, as well, where it has been shown to be safe, with pharmacokinetics similar to those of naloxone given by injection .


Eligibility criteria: Inclusion Criteria:

* Binge eating disorder (DSM-IV) and body mass index (BMI) \> 25
* Binge eating screen \> 20

Exclusion Criteria:

* Pregnancy
* Drug usage
* Retarded
* Severe mental illness

Primary outcomes:
measure: Change from baseline in frequency of binge eating
timeFrame: 0 and 24 week
Secondary outcomes:
measure: Becks depression inventory (BDI)
timeFrame: -1,0, 24 weeks
measure: Analogic binge eating craving scale (BES-VAS)
timeFrame: -1,0,24 weeks
measure: Binge eating severity scale (BES)
timeFrame: -1,0,24 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03973970: Assessing the Ability of the T-SPOT®.TB Test (IQ)
Official title: Assessing the Ability of the T-SPOT®.TB Test to Identify Those at Risk of Active Mycobacterium Tuberculosis Infection Using the Normalized Tuberculosis (TB) Specific Lymphocyte Response.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tuberculosis
Keywords: TB
Lead sponsor: Oxford Immunotec
Sponsor class: INDUSTRY
First posted: 2019-06-04
Enrollment: 201
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male and Female 18 years of age and older

Brief summary: The primary objective of this clinical research study is to demonstrate performance of the normalized TB specific lymphocyte response (NTBSLR) in identifying patients with active TB disease. The secondary exploratory objective is to demonstrate that active TB cannot be identified using an antigen-to-mitogen ratio derived from an ELISA-based IGRA.

Detailed description: This study will enroll up to 202 subjects (assumes 15 % exclusion/drop-out rate). The target number of subjects is 75 active TB (recruited from subjects presenting at TB clinics) and 100 active TB excluded (recruited from subjects in the community).

All subjects enrolled in this study will be men or women, aged 18 years or older.

Duration: 1 year

Eligibility criteria: Subject Inclusion Criteria: Cohort 1A and 1B

* Must be at least 18 years of age
* Must be able to provide informed consent
* Must be able to provide a minimum of 10 mL of whole blood at each visit
* Must be T-SPOT.TB positive
* First visit suspect TB subjects with no prior history of TB diagnosis Subject exclusion criteria: Cohort 1A and 1B
* Negative in the T-SPOT.TB test
* Previous or pre-existing confirmed TB diagnosis
* On anti-TB treatment for less than 1 week\*
* Not meeting inclusion criteria

Subject inclusion criteria: Cohort 2A and 2B

* Must be at least 18 years of age
* Must be able to provide informed consent
* Must be able to provide a minimum of 10 mL of whole blood at each visit
* Must be T-SPOT.TB positive
* No prior history of TB diagnosis

Subject exclusion criteria: Cohort 2A and 2B

* Negative T-SPOT.TB test
* Previous or pre-existing confirmed TB diagnosis
* On anti-TB treatment
* Symptoms of active TB
* Not meeting inclusion criteria

Primary outcomes:
measure: NTBSLR
timeFrame: 2 year
Secondary outcomes:
measure: IGRA
timeFrame: 2 year
Other outcomes:
Locations:
city: Brownsville
country: United States
facility: University of Texas Health
state: Texas
Study officials:
affiliation: UTHealth Houston, School of Public Health
name: Blanca Restrepo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05722470: Eating Disorders Among Adolescents
Official title: Assessment of Prevalence of Eating Disorder Among Adolescents and it's Risk Factors
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Eating Disorders
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-02-10
Enrollment: 200
Sex: ALL
Minimum age (years): 10
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Age between 10 and 18 years old Males and females

Brief summary: The aim of the present study is to evaluate the prevalence of eating disorder among adolescents. Also, to evaluate psychiatric comorbidity, sleep problems, alexithymia and emotion dysregulation associated with patients had eating disorders. In addition, to identify possible risk factors associated with eating disorder among adolescents.


Eligibility criteria: Inclusion Criteria:

* Age between 10 to 18 years old.
* Males and females are included.

Exclusion Criteria:

* - participants were previously diagnosed with any psychiatric disorder.

Primary outcomes:
measure: eating disorders among adolescents
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06622070: A Study of SPY002-072 in Healthy Volunteers
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY002-072 in Healthy Participants
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Spyre Therapeutics, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Altasciences Company Inc.
First posted: 2024-10-01
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: BASIC_SCIENCE

Brief summary: This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants.


Eligibility criteria: Inclusion Criteria:

* Healthy men and women
* Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits

Exclusion Criteria:

* Participation in more than one cohort
* Evidence of clinically significant abnormality or disease
* Known history of illicit drug use or drug abuse, cannabis/cannabinoid use, harmful alcohol use (at the Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study agent
* History of severe allergic reactions or hypersensitivity
* Donation or loss of ≥ 1 unit of whole blood within 1 month prior to dosing

Primary outcomes:
measure: Treatment emergent adverse events
timeFrame: Up to 40 weeks
Secondary outcomes:
measure: Cmax
timeFrame: Up to 40 weeks
measure: t1/2
timeFrame: Up to 40 weeks
measure: Tmax
timeFrame: Up to 40 weeks
measure: ADA
timeFrame: Up to 40 weeks
measure: AUC
timeFrame: Up to 40 weeks
Other outcomes:
Locations:
city: Cypress
country: United States
facility: Spyre Site 2
state: California
city: Montréal
country: Canada
facility: Spyre Site 1
state: Quebec
Study officials:
affiliation: Spyre Therapeutics
name: Joshua Friedman, MD
role: STUDY_CHAIR
References: